Adopted opinions and previous consultations on applications for authorisation

Adopted opinions and previous consultations on applications for authorisation

Adopted opinions and previous consultations on applications for authorisation

This page provides further information on the applications for authorisation or review reports, which have undergone consultation. The applications for authorisation are in the opinion development phase until the final opinions of the Committees for Risk Assessment and Socio-economic Analysis have been adopted and sent to the European Commission. Its decision-making process can be followed through the comitology register, where further information is published about the REACH Committee's past and upcoming meetings.

On 1 February 2020, the United Kingdom (UK) withdrew from the EU. The transition period provided by the withdrawal agreement ended on 31 December 2020. As of 1 January 2021, an application for an authorisation submitted by a person established in the UK (except Northern Ireland) is no longer valid in the EU, unless that application has been transferred to a legal entity established in the EU or Northern Ireland before the end of the transition period. Therefore, authorisation applications and decisions in so far as these concern persons established in the UK (except Northern Ireland) are no longer considered valid. 

 

There are currently no ongoing consultations.
 
0248-01 Initial 4-Nonylphenol, branched and linear, ethoxylated - - FYSOL SAS [name of applicant in the original application: OCV Chambéry France S.A.S. updated due to a notified legal entity change] Mixing by the Applicant of a NPnEO-containing epoxy resin, resulting in mixtures containing < 0.1% w/w of NPnEO for the manufacture of glass fiber articles for critical composite helicopter parts, that is exempt from authorisation under REACH Art. 56(6)(a) Commission decided Details
0247-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Boehringer Ingelheim RCV GmbH & Co KG Use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated as a detergent in the purification of lipidated OspA protein subsequently used for manufacturing of Lyme disease vaccine candidate. Commission decided Details
0246-01 Initial 2,2'-dichloro-4,4'-methylenedianiline (MOCA) 202-918-9 101-14-4 Courbis Synthèse Annovi S.r.l.; Dansk Elastomer A/S; Durlast S.r.l.; Pieffe S.r.l.; Policart S.r.l.; R.B.M. Italia S.r.l.; Tecnocaucho S.A.; Tegea S.r.l.; Optibelt Urethane Belting Ltd.; Productos Salinas S.A.; V.M. SPA Industrial use of 2,2'-Dichloro-4,4'-methylenedianiline (MOCA) in the manufacture of hot cast polyurethane products Commission decided Details
0245-01 Initial Chromium trioxide 215-607-8 1333-82-0 NEWFORM S.P.A. Electroplating of different types of substrates using Chromium Trioxide to achieve functional surfaces with high durability and a bright or matt silvery appearance for sanitary applications Opinions adopted Details
0244-02 Initial Chromium trioxide 215-607-8 1333-82-0 CROMAPLAST S.p.A. Industrial use of CrO3 in the chrome plating of automotive plastic components Opinions adopted Details
0244-01 Initial Chromium trioxide 215-607-8 1333-82-0 CROMAPLAST S.p.A. Industrial use of CrO3 in the pre-treatment (etch) in the chrome plating process of automotive plastic components Opinions adopted Details
0243-01 Review report Trichloroethylene 201-167-4 79-01-6 DOMO Caproleuna GmbH Industrial use as an extraction solvent for the purification of caprolactam from caprolactam oil Commission decided Details
0242-01 Review report Trichloroethylene 201-167-4 79-01-6 Microporous GmbH Trichloroethylene used as extraction solvent in the manufacture of polyethylene separators for lead-acid batteries Commission decided Details
0241-01 Initial Chromium trioxide 215-607-8 1333-82-0 Gessi S.p.A.
San Marco Rubinetteria S.r.l.
Use of chromium trioxide for electroplating of metal substrates with the purpose of creating a long-lasting high durability surface with bright look for kitchen and bathroom sanitaryware (functional plating with decorative character) Opinions adopted Details
0240-01 Initial 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated - - Alexion Pharma International Operations Unlimited Company Industrial use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated for virus inactivation in the manufacture Andexanet alfa for treatment of adult patients treated with a direct factor Xa (FXa) inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding Commission decided Details